Media Library

Novartis has been in the front ranks of a revolution in the treatment of malaria, launching the first fixed-dose artemisinin-based combination therapy (ACT) in 1999 and the first dispersible pediatric ACT developed in partnership with Medicines for Malaria Venture (MMV) in 2009.

Reimagining the management of sickle cell disease in Africa. Sickle cell disease is a hereditary and life-threatening condition that causes ongoing vascular damage and repeated injury to blood vessels and organs. This lifelong illness often takes an extreme emotional, physical, and financial toll on patients and their families.

The fight against leprosy is one of the greatest public health successes in history. For more than 30 years, Novartis and the Novartis Foundation have been working with partners around the world to eliminate leprosy.

The journalist handbook with a special focus on Neuroendocrine Tumors (NET).

Our understanding of lung cancer has changed from one disease to many subtypes.

Myelodysplastic syndromes (MDS) are a diverse group of diseases in which too few healthy blood cells are produced in the bone marrow.

Iron is an essential element in the human body mostly found in red blood cells. Iron helps cells “breathe” by carrying oxygen to cells and tissues, and is essential to giving the body energy and having a properly functioning immune system.

Sickle cell disease (SCD) is a hereditary blood disorder characterized by sickleshaped red blood cells.

Thalassemia refers to a diverse family of genetic disorders characterized by an underproduction of hemoglobin, a protein in red blood cells that carries oxygen.

Despite progress, billions of people still live at the bottom of the pyramid and lack access to essential healthcare. Our Healthy Family programs aim at expanding access to community education, improved infrastructure and affordable healthcare products in India, Vietnam and Kenya – in a sustainable way.

The burden of noncommunicable diseases is increasing in the developing world, where people often have limited resources to get the care they need. Novartis Access aims to bring affordable treatments for key chronic diseases like cardiovascular diseases, diabetes and cancer to patients in lower-income countries.

Non-alcoholic steatohepatitis (NASH) is a more severe, progressive form of non-alcoholic fatty liver disease (NAFLD). The prevalence of NAFLD in Western countries is 20-30%, and it is estimated that 2-3% of the population has NASH.